TY - JOUR
T1 - Safety and Efficacy of Topical Calcineurin Inhibitors in the Treatment of Facial and Genital Psoriasis
T2 - A Systematic Review
AU - Amiri, Diva
AU - Schwarz, Christopher Willy
AU - Gether, Lise
AU - Skov, Lone
PY - 2023/3/14
Y1 - 2023/3/14
N2 - Facial and genital psoriasis impairs quality of life and is challenging to treat because of increased percutaneous penetration and, consequently, increased risk of adverse effects. Topical calcineurin inhibitors are recognized as a valid off-label treatment for these sensitive skin areas, but data on safety and efficacy are limited. This systematic review of the literature included 24 of 3,322 studies (5 randomized controlled trials, 9 open-label studies, 2 case series and 8 case reports). All studies demonstrated positive efficacy; 11 studies found statistically significant reductions in psoriasis severity. Local stinging, burning and itching were the most common short-term adverse effects and were reported in 18 studies. Topical calcineurin inhibitors appear to have an important role in the treatment of facial and genital psoriasis. The drugs are effective and generally well-tolerated with few adverse effects.
AB - Facial and genital psoriasis impairs quality of life and is challenging to treat because of increased percutaneous penetration and, consequently, increased risk of adverse effects. Topical calcineurin inhibitors are recognized as a valid off-label treatment for these sensitive skin areas, but data on safety and efficacy are limited. This systematic review of the literature included 24 of 3,322 studies (5 randomized controlled trials, 9 open-label studies, 2 case series and 8 case reports). All studies demonstrated positive efficacy; 11 studies found statistically significant reductions in psoriasis severity. Local stinging, burning and itching were the most common short-term adverse effects and were reported in 18 studies. Topical calcineurin inhibitors appear to have an important role in the treatment of facial and genital psoriasis. The drugs are effective and generally well-tolerated with few adverse effects.
KW - Humans
KW - Calcineurin Inhibitors/adverse effects
KW - Quality of Life
KW - Psoriasis/diagnosis
KW - Skin Diseases/drug therapy
KW - Genitalia
KW - Dermatologic Agents/adverse effects
UR - http://www.scopus.com/inward/record.url?scp=85150311510&partnerID=8YFLogxK
U2 - 10.2340/actadv.v103.6525
DO - 10.2340/actadv.v103.6525
M3 - Review
C2 - 36916954
SN - 0001-5555
VL - 103
SP - adv00890
JO - Acta Dermato-Venereologica
JF - Acta Dermato-Venereologica
M1 - adv00890
ER -